Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) LT-Debt-to-Total-Asset : 0.00 (As of Jan. 2020)

View and export this data going back to 2007. Start your Free Trial

What is Cotinga Pharmaceuticals LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Cotinga Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Jan. 2020 was 0.00.

Cotinga Pharmaceuticals's long-term debt to total assets ratio stayed the same from Jan. 2019 (0.00) to Jan. 2020 (0.00).

Cotinga Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

The historical data trend for Cotinga Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cotinga Pharmaceuticals LT-Debt-to-Total-Asset Chart

Cotinga Pharmaceuticals Annual Data

Trend

Apr10

Apr11

Apr12

Apr13

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

Cotinga Pharmaceuticals Quarterly Data
	Apr15	Jul15	Oct15	Jan16	Apr16	Jul16	Oct16	Jan17	Apr17	Jul17	Oct17	Jan18	Apr18	Jul18	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Cotinga Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Cotinga Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Apr. 2019 is calculated as

LT Debt to Total Assets (A: Apr. 2019 )	=	Long-Term Debt & Capital Lease Obligation (A: Apr. 2019 )	/	Total Assets (A: Apr. 2019 )
	=	0	/	0.933
	=

Cotinga Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jan. 2020 is calculated as

LT Debt to Total Assets (Q: Jan. 2020 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jan. 2020 )	/	Total Assets (Q: Jan. 2020 )
	=	0	/	0.695
	=

Cotinga Pharmaceuticals (OTCPK:COTQF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Cotinga Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Cotinga Pharmaceuticals's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cotinga Pharmaceuticals Inc (OTCPK:COTQF) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

82 Richmond Street East, The Canadian Venture Building, Toronto, ON, CAN, M5C1P1

Website

http://www.cotingapharma.com

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Headlines

From GuruFocus

Cotinga Pharmaceuticals Reports Fiscal 2018 Third Quarter Financial and Operating Results

By GlobeNewswire GlobeNewswire • 04-03-2018

Cotinga Pharmacueticals Announces Closing of Unit Offering

By GlobeNewswire GlobeNewswire • 05-22-2019